Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial

The Lancet

Volumn 375, Issue 9709, 2010, Pages 123-131

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; LAMIVUDINE PLUS ZIDOVUDINE; NEVIRAPINE; RITONAVIR; TENOFOVIR DISOPROXIL;

ADULT; AFRICA; ANEMIA; ARTICLE; AUTOMATION; CD4 LYMPHOCYTE COUNT; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; HAZARD RATIO; HEMATOLOGICAL PARAMETERS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY DIAGNOSIS; LIPOATROPHY; LIPODYSTROPHY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; NEUTROPENIA; OPEN STUDY; OUTCOME ASSESSMENT; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TREATMENT DURATION; TREATMENT OUTCOME; VIRUS LOAD; WORLD HEALTH ORGANIZATION;

EID: 73449090396     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)62067-5     Document Type: Article

References (25)

1. UNAIDS. The global economic crisis and HIV prevention and treatment programmes: vulnerabilities and impact (June, 2009). http://data.unaids.org/pub/Report/2009/jc1704_econcrisis_hivresponse_en.pdf (accessed Dec 2, 2009).
2. World Bank. Averting a human crisis during the global downturn: policy options from the World Bank's Human Development Network (2009). http://siteresources.worldbank.org/NEWS/Resources/AvertingTheHumanCrisis.pdf (accessed Dec 2, 2009).
3. Gilks C.F., Crowley S., Ekpini R., et al. The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet 368 (2006) 505-510
4. Coutinho A, Mermin J, Ekwaru J, et al. Utility of routine viral load, CD4 cell count, and clinical monitoring among HIV-infected adults in Uganda: a randomized trial. 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA; Feb 3-6, 2008. Abstract 125.
5. WHO. Antiretroviral therapy for HIV infection in adults and adolescents in resource-limited settings: towards universal access. Recommendations for a public health approach (2006), World Health Organization, Geneva
6. Dart Trial Team. Twenty-four-week safety and tolerability of nevirapine vs. abacavir in combination with zidovudine/lamivudine as first-line antiretroviral therapy: a randomized double-blind trial (NORA). Trop Med Int Health 13 (2008) 6-16
7. Dart Trial Team. Fixed duration interruptions are inferior to continuous treatment in African adults starting therapy with CD4 cell counts <200 cells/microl. AIDS 22 (2008) 237-247
8. Division of AIDS. Table for grading severity of adult adverse experiences (1992), National Institute of Allergy and Infectious Diseases, Bethesda
9. WHO. Antiretroviral therapy for HIV infection in adults and adolescents in resource-limited settings: towards universal access. Recommendations for a public health approach (2006), World Health Organization, Geneva
10. Interim proposal for a WHO Staging System for HIV infection and Disease. Wkly Epidemiol Rec 65 (1990) 221-224
11. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. Clinical safety data management: definitions and standards for expedited reporting (E2A) (1994). http://www.emea.europa.eu/pdfs/human/ich/037795en.pdf (accessed Dec 2, 2009).
12. Peto R., Pike M.C., Armitage P., et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer 34 (1976) 585-612
13. Dart Virology Group and Trial Team. Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa. AIDS 20 (2006) 1391-1399
14. Cockcroft D.W., and Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 16 (1976) 31-41
15. Munderi P, Watera C, Nakiyingi J, et al. Survival and causes of death, 2 years after introduction of antiretroviral therapy in Africa: a historical cohort comparison in Entebbe, Uganda. XVI International AIDS Conference. Toronto, Canada; Aug 13-18, 2006. Abstract THLB0208.
16. Boulle A., Bock P., Osler M., et al. Antiretroviral therapy and early mortality in South Africa. Bull World Health Organ 86 (2008) 678-687
17. Bussmann H., Wester C.W., Ndwapi N., et al. Five-year outcomes of initial patients treated in Botswana's National Antiretroviral Treatment Program. AIDS 22 (2008) 2303-2311
18. Lawn S.D., Little F., Bekker L.G., et al. Changing mortality risk associated with CD4 cell response to antiretroviral therapy in South Africa. AIDS 23 (2009) 335-342
19. Zhang F., Dou Z., Ma Y., et al. Five-year outcomes of the China National Free Antiretroviral Treatment Program. Ann Intern Med 151 (2009) 241-251 W-52.
20. Leger P., Charles M., Severe P., Riviere C., Pape J.W., and Fitzgerald D.W. 5-year survival of patients with AIDS receiving antiretroviral therapy in Haiti. N Engl J Med 361 (2009) 828-829
21. Hosseinipour M.C., van Oosterhout J.J., Weigel R., et al. The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS 23 (2009) 1127-1134
22. Kantor R., Diero L., Delong A., et al. Misclassification of first-line antiretroviral treatment failure based on immunological monitoring of HIV infection in resource-limited settings. Clin Infect Dis 49 (2009) 454-462
23. Medina Lara A, Kigozi J, Amurwon J, et al. Cost effectiveness analysis of routine laboratory or clinically driven strategies for monitoring anti-retroviral therapy in Uganda and Zimbabwe (DART Trial). 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Cape Town, South Africa; July 19-22, 2009. Abstract TUSS103.
24. Phillips A.N., Pillay D., Miners A.H., Bennett D.E., Gilks C.F., and Lundgren J.D. Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model. Lancet 371 (2008) 1443-1451
25. WHO. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector: a progress report. http://www.who.int/hiv/pub/2009progressreport/en/index.html (accessed Oct 18, 2009).